Home > Oncology > ESMO 2022 > Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Overall survival benefit of abiraterone in mHSPC is maintained for 7 years

Presented By
Dr Gerhardt Attard, UCL Cancer Institute London, UK
Conference
ESMO 2022
Trial
STAMPEDE
Addition of enzalutamide to abiraterone acetate plus prednisone (AAP) does not improve overall survival (OS) of patients with metastatic hormone-sensitive prostate cancer (mHSPC), results from STAMPEDE demonstrated. In addition, it was shown that the survival benefit of AAP when added to ADT is maintained at 7 years. In recent years, it has been demonstrated that, in men with mHSPC, addition of either AAP or enzalutamide to androgen deprivation therapy (ADT) improves outcomes [1,2]. Combining AAP and enzalutamide has been shown to benefit progression-free survival (PFS), but not OS, in patients with metastatic castration-resistant prostate cancer (mCRPC) [3]. However, the benefit of combining AAP and enzalutamide in mHSPC is unknown. In addition, survival outcomes of mHSPC on ADT plus AAP or AAP/enzalutamide beyond 5 years have not been reported. Comparison of 2 randomised phase 3 trials in the multi-arm, multi-stage STAMPEDE protocol (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on